Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – A hostile takeover bid, a Senate hemp vote that reset the enforcement calendar without solving anything, a state tax repeal with constitutional teeth, a dense Q2 earnings wave, and two landmark banking deals – the fortnight gave the industry more to process than most quarters do.

1. Hostile M&A & Corporate Restructuring

The period’s most-watched development arrived August 13, when Curaleaf Holdings launched a $272 million hostile takeover bid for Aurora Cannabis, bypassing Aurora’s board after two rounds of private outreach [June 23 and July 70] produced no engagement. The offer includes US$4.00 per share at a 45% premium to Aurora’s 30-day VWAP, structured as 0.3463 Curaleaf subordinate voting shares plus US$0.75 cash, capped at US$5.00 per share. Curaleaf projects the combined entity would generate over US$1.5 billion in trailing revenue and nearly US$350 million in adjusted EBITDA. Aurora pushed back, noting the $5.00 cap falls below where its shares traded in late 2025, and established an independent special committee to evaluate alternatives.

The bid’s real logic lives in Aurora’s Q1 FY 2027 results. International medical Cannabis revenue rose 17% to $43.3 million on German patient demand even as total revenue fell 9% to $67.6 million on Canadian federal reimbursement cuts. Aurora holds $149.1 million in cash with no debt, plus more than 50 metric tons of annual EU-GMP cultivation capacity – the assets Curaleaf is actually pricing, not Aurora’s declining domestic adult-use position.

Trulieve completed its redomiciliation from British Columbia to Delaware with 99.5% shareholder support. The move, following the company’s June 2026 NYSE uplist as the first U.S. Cannabis company on a major American exchange, removes the cross-border legal friction that blocked institutional mandates and index eligibility. Trulieve operates entirely in the U.S. across Florida, Georgia, Pennsylvania, and West Virginia. Delaware incorporation aligns the corporate wrapper with that reality.

2. Capital Markets & Banking Access

Institutional banking reached Cannabis through two separate channels this fortnight. High Tide closed a C$40 million senior secured credit facility with Bank of Montreal – a C$25 million revolving facility plus a C$15 million delayed-draw term loan, marking the first Big Five Canadian chartered bank senior lending relationship the Alberta-based retailer has ever held. The deal landed one day after High Tide issued Q3 2026 guidance projecting C$195–$200 million in revenue [30–34% growth year-over-year] and C$15.2–$16.5 million in adjusted EBITDA, both clearing the top end of every analyst estimate on FactSet.

Vireo Growth was the period’s most operationally active company. The MSO closed its $49 million Colorado PharmaCann acquisition, absorbing 17 LivWell dispensaries to reach 56 Colorado locations across a 10-state, 170-plus dispensary network, while simultaneously announcing a BMO-arranged $65 million senior secured asset-based revolving credit facility [expandable to $105 million] structured through non-Cannabis subsidiaries at SOFR-plus-1.75% pricing. Vireo also authorized a share buyback program, a capital allocation signal that stands out in a sector where cash conservation has been near-universal posture.

3. Federal & State Policy

The U.S. Senate voted 61-32 to push the federal hemp THC ban deadline from November to December 11, 2026, tabling Sen. Ted Budd’s (R) amendment to keep the original enforcement schedule while passing the underlying continuing resolution 90-6. The ban, enacted in November 2025, would cap hemp products at 0.4 milligrams of total THC per container and redefine hemp at 0.3% total THC, pulling THCA into the compliance calculation. Synthetic cannabinoids remain on track for November 12 prohibition regardless. The Lawful Hemp Protection Act, introduced July 22, is the most developed legislative vehicle in play, but the House’s post-Labor Day calendar is compressed. December 11 is now the operative date. No legislative resolution is guaranteed.

In Michigan, lawmakers moved in both chambers to repeal the state’s 24% wholesale Cannabis tax, enacted in January 2026 to fund road repair. The tax raised roughly $34 million in its first four months against a $105 million projection – a $70 million quarterly shortfall. House Bill 6224 and the earlier Senate Bill 810 have bipartisan cosponsors. The Michigan Cannabis Industry Association has filed a parallel constitutional challenge arguing the legislature lacked the three-quarters majority required to amend a voter-approved law.

New York opened an outdoor Cannabis sales channel for licensed operators, a new revenue access point in a market still working through years of implementation delays.

4. Q2 Earnings Wave

Earnings season produced a steady flow of Q2 and fiscal updates. Major multistate Cannabis operators Curaleaf, Verano, Green Thumb Industries, Cresco Labs, Trulieve, Ascend Wellness, LEEF Brands, Glass House Brands, RHYTHM, Organigram, and Vireo Growth all reported Q2 financial and operational results alongside broader corporate moves.

The aggregate read: balance sheet discipline is separating operators more decisively than revenue scale, with clean-debt operators widening their distance from those still carrying legacy financing costs under sustained price compression. Many operators pointed to sequential improvements in domestic performance, tighter cost control, and selective market focus. Revenue stability and adjusted profitability metrics received particular attention from investors tracking the post-rescheduling environment.

5. Brands & Retail Expansion

Tyson 2.0 partnered with Reborn Roots to enter Rhode Island retail, extending the celebrity Cannabis brand category into another licensed adult-use market where name recognition carries outsized shelf weight.

6. Psychedelics Policy & the Research Frontier

Puerto Rico’s governor ordered a formal psychedelics research program, placing the territory alongside Colorado among the small number of U.S. jurisdictions treating psychedelics research as a public health and economic development priority ahead of any federal scheduling action.

On the conference side, the PSYCH Symposium rebranded as Mind Forward for its upcoming London event – a pivot toward institutional healthcare audiences that reflects the sector’s broader maturation.

HCN Insight

The Curaleaf-Aurora bid is the most noteworthy Cannabis M&A move in years, and it is being underread as a North American consolidation play when it is actually a global medical supply chain thesis. Curaleaf wants Aurora’s EU-GMP production capacity and its regulated market access across Germany, Poland, and Australia. Not its Canadian adult-use legacy, which Aurora has been winding down for two years. Aurora’s international medical revenue grew 17% in Q1 FY 2027 while domestic revenues contracted 25%. That divergence is the asset Curaleaf is pricing. A combined entity with more than US$1.5 billion in projected revenue would control more EU-GMP output than any other Cannabis company operating across both North American and European regulated markets. The board fight will likely run into Q4. What matters is the destination. This transaction, or whatever competing offer it surfaces, will determine which operator controls the EU-GMP supply routes that European demand growth is now making genuinely valuable.

The Senate hemp vote and Michigan’s tax repeal fight sit in the same analytical category. They are both cases of policy running into market reality faster than legislators planned. The hemp THC ban extension to December 11 bought time without resolving the core regulatory gap. The Lawful Hemp Protection Act has a credible structure, but the House’s post-Labor Day calendar is compressed, and operators should model December 11 as a hard cliff rather than a soft deadline. Michigan’s 24% wholesale levy collapsed within one fiscal quarter; collections ran at roughly one-third of projections, and the resulting constitutional challenge could establish that voter-approved Cannabis frameworks require a supermajority to amend. A successful repeal would carry precedent weight for operators in other high-tax states watching similar levies move through their own legislative pipelines.

The BMO facilities for both Vireo and High Tide are not two separate news items. They are the same institutional thesis arriving at two operators simultaneously. Conventional lenders are finding structural pathways into Cannabis without waiting for SAFER Banking Act passage. Vireo’s asset-based revolving credit is secured through non-plant-touching subsidiaries at conventional spreads; High Tide’s C$40 million package is its first Big Five bank relationship. Both signal that cost-of-capital differentiation is now a real competitive variable in the sector, and operators who have built these banking relationships through creative structuring will have a durable advantage as the Q2 earnings cycle confirms that margin compression is not letting up in most adult-use state markets.

Trulieve’s Delaware redomicile completes the same logic at the corporate level, aligning legal structure with operational geography to remove barriers to institutional capital. The 99.5% shareholder vote signals institutional consensus. The question now is how quickly index inclusion translates into actual inflows.